Breaking News

Recipharm, Arcturus Ink LUNAR-COV19 Vax Mfg. Pact

Recipharm to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing Phase I/II clinical trial.

By: Contract Pharma

Contract Pharma Staff

Recipharm, a contract development and manufacturing organization (CDMO), has entered into an agreement with Arcturus Therapeutics, a U.S. based clinical-stage messenger RNA medicines company focused infectious disease vaccines, to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing Phase I/II clinical trial. The companies are working to secure commercial manufacturing production for 2021 and the future. Thomas Eldered, CEO of Recipharm said: “W...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters